# A PK Study Comparing MB05, EU-sourced Synagis® and US-sourced Synagis® in Healthy Volunteers.

> **NCT05121246** · PHASE1 · COMPLETED · sponsor: **mAbxience Research S.L.** · enrollment: 150 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** MB05 (Proposed palivizumab biosimilar)
- **DRUG:** EU-Synagis®
- **DRUG:** US-Synagis®

## Key facts

- **NCT ID:** NCT05121246
- **Lead sponsor:** mAbxience Research S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-15
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05121246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05121246, "A PK Study Comparing MB05, EU-sourced Synagis® and US-sourced Synagis® in Healthy Volunteers.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05121246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*